Novavax says its COVID-19 vaccine prevents severe cases from U.K., South African variants

Novavax vaccine results released
(Image credit: Justin Tallis/AFP/Getty Images)

Novavax announced Thursday that its COVID-19 vaccine had proved effective, especially at preventing serious illness or death, in late-stage trials in Britain and South Africa, home to two of the more contagious variants spreading around the world.

The Maryland biotech firm said that its final analysis of its British trial found the vaccine 96 percent effective against the original strain and 86 percent effective against the B.1.1.7 variant, for an overall protection rate of 90 percent. In the smaller South African trial, the vaccine was 55 percent effective at preventing COVID-19 cases among people without HIV, and 49 percent effective when the HIV-positive subset was included. There were zero cases of severe illness in either country among trial participants who got the vaccine, Novavax said, versus 10 severe cases in people given placebos.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.